SIGYN THERAPEUTICS INC
1.9000+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · SIGY · USD
Key Stats
Market Cap
3.05MP/E (TTM)
-Basic EPS (TTM)
-2.52Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Sigyn Therapeutics posted a Q2 net loss of $1.5M, up from $862K last year, while YTD loss widened to $2.1M from $1.6M amid zero revenue and a 17.6% drop in operating expenses to $1.0M, driven by slashed R&D spending. Cash dwindled to $459 from $12K at year-end, with operating cash burn at $447K offset by $435K in convertible note proceeds; free cash flow not disclosed in the 10-Q. Convertible debt swelled to $2.3M net, mostly short-term at rates up to 273%, while the office lease ended in May, trimming liabilities. EPS held steady at -$0.90 quarterly on 1.6M shares, with anti-dilutive effects from 2M potential shares flagged. Yet cash is nearly gone. Board and CSO quit in August over lapsed D&O insurance, spotlighting governance risks.
8-K
Funding secured, board resigns
Sigyn Therapeutics secured up to $550,000 in one-year 8% convertible notes from Lambda Venture Partners on August 8, 2025, issuing an initial $110,000 tranche for $100,000 net proceeds after fees. Yet three board members resigned effective August 7-8, 2025, due to the lapse of D&O insurance on August 4, with no replacement yet. This funding bolsters working capital amid governance shakeup.
10-Q
Q1 FY2025 results
Sigyn Therapeutics posted a narrower Q1 FY2025 net loss of $668,564, down 11.8% y/y from $758,088, as operating expenses fell 13.3% to $546,059 on slashed R&D outlays while compensation rose. No revenue yet, but cash burn eased slightly to $294,446 from operations, offset by $295,197 in fresh convertible note proceeds, leaving $12,895 in cash against $5.2M liabilities, including $2.2M net convertibles (up 15.8% q/q, derived) and $213K promissory notes—defaults on $485K notes loom amid restructuring talks. EPS improved to $(0.42) from $(0.62), matching 1.6M diluted shares with no anti-dilution flags. Lease terminated in May 2025 for $32.7K payout. Yet competition from better-resourced rivals shadows clinical progress.
10-K
FY2024 results
Sigyn Therapeutics posted a net loss of $3.3 million for FY2024 ended December 31, 2024, an improvement from $4.1 million in 2023, driven by lower interest expenses on convertible debt amid ongoing pre-revenue development of blood purification devices. Operating expenses rose modestly 2.6% to $2.5 million, with R&D steady at $773K while investor relations costs jumped to support brand awareness; no quarterly breakdowns disclosed, but annual cash burn eased to $872K from $1.4 million, fueled by $873K in financing inflows. Liquidity remains precarious with $12K cash against $4.7 million liabilities, including $2.1 million in notes now in default and pending restructurings. No guidance issued. Regulatory delays could stall quarterly progress.
8-K
CFO retires; viral therapy spotlighted
Sigyn Therapeutics' CFO Gerald DeCiccio retired on February 26, 2025, with no disagreements noted, prompting CEO James Joyce to step in as interim CFO while DeCiccio continues via consulting agreement. The company highlighted Sigyn Therapy's potential against emerging viral threats like mpox and Ebola in a CEO letter, emphasizing blood purification for viruses, toxins, and cytokines. This positions therapy for ESRD studies and pandemic countermeasures. Forward-looking risks include clinical advancement hurdles.
IPO
Employees
Sector
Industry
CALC
CalciMedica, Inc.
2.97-0.10
CTSO
Cytosorbents Corporation
0.78-0.05
CYDY
CytoDyn Inc.
0.24-0.01
DSGN
Design Therapeutics, Inc.
6.49-0.19
SABS
SAB Biotherapeutics, Inc.
3.04+0.02
SIGA
SIGA Technologies Inc.
8.13-0.31
SLXN
Silexion Therapeutics Corp
3.44+0.01
SYBX
Synlogic, Inc.
1.77-0.04
TOVX
Theriva Biologics, Inc.
0.31-0.02
VIR
Vir Biotechnology, Inc.
5.91-0.52